| Literature DB >> 24564451 |
Jai K Das, Zohra S Lassi, Rehana A Salam, Zulfiqar A Bhutta.
Abstract
INTRODUCTION: Diarrhea and pneumonia are the two leading causes of mortality in children under five. Improvements have occurred over the past two decades but the progress is slow to meet the MDG-4.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24564451 PMCID: PMC3953053 DOI: 10.1186/1471-2458-13-S3-S29
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Figure 1Search strategy flow diagram
Effect of community based interventions on the coverage of commodities/services for diarrhea and pneumonia
| Quality Assessment | Summary of Findings | |||||||
|---|---|---|---|---|---|---|---|---|
| Directness | No of events | |||||||
| No of studies | Design | Limitations | Consistency | Generalizability to population of interest | Generalizability to intervention of interest | Intervention | Control | Relative Risk (95% CI) |
| Two | RCT/Quasi | No significant heterogeneity so a fixed effect model used | Both studies suggest benefit | One study from Asia and one from Africa | WHO case management by local health workers | 344 | 327 | 1.13 [1.08, 1.18] |
| Four | CRCT | Significant heterogeneity so a random effect model used | Two studies show benefit | All studies from South Asia | Promotion of use of ORS and zinc by CHWs | 3562 | 4691 | 1.09 [1.06, 1.12] |
| Six | RCT/Quasi | Significant heterogeneity so a random effect model used | All the studies suggest benefit | All studies are from Asia | All the studies had community education while four studies had combined intervention of promotion and zinc therapy and two had free distribution of ORS | 10446 | 3990 | 2.60 [1.59, 4.27] |
| Two | Before/After | No major limitation | All the studies suggest benefit | Both studies were from Africa | One study had combined intervention of promotion of zinc therapy | 143 | 86 | 1.75 [1.48, 2.07] |
| Four | cRCT | Significant heterogeneity across studies so a random effect model used | All Studies suggest benefit | All studies from South Asia | CHWs provided education and promoted use of ORS and zinc | 5554 | 14 | 29.79 [12.33, 71.97] |
| Antibiotic Use for Diarrhea: moderate outcome specific quality of evidence | ||||||||
| Four | cRCT | Significant heterogeneity across studies so a random effect model used | All studies suggested a decline in the use of antibiotics | All studies from South Asia | CHWs provided education and promoted use of ORS and zinc | 639 | 3083 | 0.25 [0.12, 0.51] |
| One | Before/After | Decline in the use of antibiotics | Study conducted in Mali | CHWs provided education and promoted use of ORS and zinc | 104 | 130 | 0.83 [0.69, 0.99] | |
| Antibiotic Use for Pneumonia: moderate outcome specific quality of evidence | ||||||||
| One | Quasi | Study Conducted in Uganda | WHO case management by local health workers | 187 | 319 | 1.13 [0.99, 1.30] | ||
| Treatment Failure Rates for ARI/Pneumonia: moderate outcome specific quality of evidence | ||||||||
| Two | cRCT | No significant heterogeneity so a fixed effect model used | Both studies suggest benefit | One study from Asia and one from Africa | WHO case management by local health workers | 228 | 314 | 0.60 [0.51, 0.70] |
Figure 2Forest plot of effect of community based interventions on the use of ORS for diarrhea
Quality assessment of studies of community case management for the treatment of pneumonia
| Quality Assessment | Summary of Findings | |||||||
|---|---|---|---|---|---|---|---|---|
| Directness | No of events | |||||||
| No of studies | Design | Limitations | Consistency | Generalizability to population of interest | Generalizability to intervention of interest | Intervention | Control | Relative Risk (95% CI) |
| Four | Concurrent | No Major | 3 of 4 studies show benefit | Africa and Asia | 3 of 4 studies WHO case management by local health workers | 384 | 686 | 0.58 (0.44–0.77) |
| Six | Concurrent | No major limitations | Heterogeneity from meta-analysis, All studies show benefit | Africa and Asia | 4 of 6 studies WHO case management | 916 | 1510 | 0.59 (0.46–0.75) |
| Two | Before/After | High ALRI incidence | Heterogeneity from meta-analysis, All studies show benefit | Asia | 1 of 2 studies WHO case management | 7 | 34 | 0.36 (0.16–0.82) |
| Seven | Concurrent; before/ after | See Above | Heterogeneity from meta-analysis, All studies show benefit | Africa and Asia | See Above | 917 | 1522 | 0.57 (0.44–0.75) |
| Nine | Concurrent; before/ after | See Above | Heterogeneity from meta-analysis, All studies show benefit | Africa and Asia | See Above | 938 | 1569 | 0.58 (0.50– 0.67) |
| Two | Before/After | High ALRI incidence | Both studies show benefit | Asia | 1 of 2 studies WHO case management | 10 | 24 | 0.51 (0.24–1.07) |
| ALRI-specific mortality 0-4 years: moderate outcome specific quality of evidence | ||||||||
| Eight | Concurrent | No major limitation | Five of eight studies show benefit | Africa and Asia | 6 of 8 studies WHO case management | 705 | 948 | 0.68 [0.53, 0.86] |
| Six | Before/After | No major limitation | Four of six studies show benefit | Africa and Asia | 3 of 5 studies WHO case management | 220 | 271 | 0.77 [0.54, 1.08] |
| Ten | Concurrent; before/ after | See Above | Eight of ten studies show benefit | Africa and Asia | See Above | 724 | 986 | 0.67 [0.51, 0.88] |
| Eleven | Concurrent; before/ after | See Above | Nine of eleven studies show benefit | Africa and Asia | See Above | 744 | 1032 | 0.68 [0.53, 0.88] |
| All cause mortality 0–1months: moderate outcome specific quality of evidence | ||||||||
| Five | Concurrent | No major limitation | All studies show benefit | Africa and Asia | 4 of 5 studies WHO case management | 925 | 957 | 0.73 (0.65– 0.82) |
| All-cause mortality 0–1 year: moderate outcome specific quality of evidence | ||||||||
| Six | Concurrent | No Major limitation | All studies show benefit | Africa and Asia | 4 of 6 studies WHO case management | 2095 | 2487 | 0.78 (0.71– 0.85) |
| Two | Before/After | High ALRI incidence | All studies show benefit | Asia only | 1 of 2 studies WHO case management | 41 | 100 | 0.60 (0.42–0.85) |
| Seven | Concurrent; before/ after | See above | All studies show benefit | Africa and Asia | See above | 2114 | 2524 | 0.77 (0.70– 0.85) |
| Nine | Concurrent; before/ after | See Above | All studies show benefit | Africa and Asia | See above | 2230 | 2703 | 0.79 (0.72–0.86) |
| All-cause mortality 1–4 years: low outcome specific quality of evidence | ||||||||
| Two | Before/After | High ALRI incidence | Both studies show benefit | Only Asia | 1 of 2 studies WHO case management | 43 | 82 | 0.49 (0.34–0.70) |
| All-cause mortality 0–4 years: moderate outcome specific quality of evidence | ||||||||
| Nine | Concurrent | No major limitation | Six studies show benefit | Africa and Asia | 6 of 9 studies WHO case management | 3115 | 4180 | 0.83 [0.73, 0.95] |
| Six | Before/After | No major limitation | Four studies show benefit | Africa and Asia | 3 of 6 studies WHO case management | 1141 | 1063 | 0.90 [0.64, 1.26] |
| Eleven | Concurrent; before/ after | No major limitation | See Above | Africa and Asia | See Above | 3113 | 4401 | 0.80 [0.77, 0.83] |
| Twelve | Concurrent; before/ after | No major limitation | See Above | Africa and Asia | See Above | 3214 | 4473 | 0.80 [0.77, 0.83] |
Figure 3Forest plot of effect of community case management on pneumonia mortality
Quality assessment of studies of community case management for the treatment of diarrhea
| Quality Assessment | Summary of Findings | |||||||
|---|---|---|---|---|---|---|---|---|
| Directness | No of events | |||||||
| No of studies | Design | Limitations | Consistency | Generalizability to population of interest | Generalizability to intervention of interest | Intervention | Control | Relative Risk (95% CI) |
| One | Before/ After | No major limitation | Asia Only | WHO case management by local health workers | 0 | 11 | 0.05 [0.00, 0.87] | |
| Diarrhea Specific mortality 1-4 years: low outcome specific quality of evidence | ||||||||
| One | Before/ After | No major limitation | Asia Only | WHO case management by local health workers | 3 | 1 | 2.98 [0.31, 28.63] | |
| One | Concurrent | No major limitation | Asia Only | WHO case management by local health workers | 3 | 8 | 0.56 [0.15, 2.11] | |
| Two | Before/After | No major limitation | Both studies show benefit | Asia Only | WHO case management by local health workers | 6 | 19 | 0.32 [0.13, 0.80] |
| Two | Concurrent: Before/After | No major limitation | Both studies show benefit | Asia Only | WHO case management by local health workers | 6 | 20 | 0.37 [0.15, 0.93] |
| All-cause mortality 0–4 years: moderate outcome specific quality of evidence | ||||||||
| One | Concurrent | No major limitation | Asia Only | WHO case management by local health workers | 157 | 221 | 1.06 [0.86, 1.30] | |
| Two | Before/After | No major limitation | One shows benefit | Asia Only | WHO case management by local health workers | 194 | 208 | 0.80 [0.47, 1.35] |
| Two | Concurrent; Before/After | No major limitation | One shows benefit | Asia Only | WHO case management by local health workers | 194 | 285 | 0.94 [0.78, 1.12] |
Figure 4Forest plot of effect of community case management on diarrhea mortality
Figure 5Application of standardized rules for choice of final outcome to estimate effect of community case management on pneumonia mortality